Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
1.900
+0.040 (2.15%)
At close: Sep 18, 2026, 4:00 PM EDT
1.919
+0.019 (1.02%)
After-hours: Sep 18, 2026, 7:59 PM EDT
Tenax Therapeutics Employees
As of December 31, 2025, Tenax Therapeutics had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 10 or 166.67% compared to the previous year.
Employees
16
Change (1Y)
10
Growth (1Y)
166.67%
Revenue / Employee
n/a
Profits / Employee
-$4,053,938
Market Cap
108.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 10 | 166.67% | 14 | 2 |
| Dec 31, 2024 | 6 | 0 | - | 4 | 2 |
| Dec 31, 2023 | 6 | -2 | -25.00% | 5 | 1 |
| Dec 31, 2022 | 8 | -1 | -11.11% | 7 | 1 |
| Dec 31, 2021 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Seer, Inc. | 124 |
| PolyPid | 75 |
| PMV Pharmaceuticals | 54 |
| Vivani Medical | 42 |
| Cardiff Oncology | 31 |
| Genelux | 26 |
| Black Diamond Therapeutics | 21 |
TENX News
- 10 days ago - Tenax Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 10 days ago - Tenax Therapeutics Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Filings
- 18 days ago - Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 19 days ago - Guggenheim downgrades Tenax Therapeutics on clinical, regulatory uncertainty - TheFly
- 19 days ago - Tenax Therapeutics downgraded to Neutral from Buy at Guggenheim - TheFly
- 20 days ago - Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103 - TheFly
- 21 days ago - Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 - GlobeNewsWire
- 4 weeks ago - TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire